ERC Society for Endocrinology Archive
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Endocrine-Related Cancer 8 (3) 259-263    DOI: 10.1677/erc.0.0080259
Copyright © 2001 by the Society for Endocrinology.
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (20)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Lonning, P.
Right arrow Articles by Borresen-Dale, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lonning, P.
Right arrow Articles by Borresen-Dale, A.
Endocrine Related Cancer, Vol 8, Issue 3, 259-263
Copyright © 2001 by Society for Endocrinology

Articles

Microarrays in primary breast cancer--lessons from chemotherapy studies

PE Lonning, T Sorlie, CM Perou, PO Brown, D Botstein, and AL Borresen-Dale


Current development in molecular techniques has extended the opportunities to explore genetic alterations in malignant tissue. There is a need to improve prognostication and, in particular, to understand the mechanisms of treatment resistance in different tumours. Gene analyses by microarrays allow concomitant analyses of several genes in concert, providing new opportunities for tumour classification and understanding of key biological disturbances. This paper outlines our continuing studies exploring prognostic and, we hope, predictive factors in breast cancer therapy.


This article has been cited by other articles:


Home page
 JCOHome page
L. Harris, H. Fritsche, R. Mennel, L. Norton, P. Ravdin, S. Taube, M. R. Somerfield, D. F. Hayes, and R. C. Bast Jr
American Society of Clinical Oncology 2007 Update of Recommendations for the Use of Tumor Markers in Breast Cancer
J. Clin. Oncol., November 20, 2007; 25(33): 5287 - 5312.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
R. Mehra, S. Varambally, L. Ding, R. Shen, M. S. Sabel, D. Ghosh, A. M. Chinnaiyan, and C. G. Kleer
Identification of GATA3 as a Breast Cancer Prognostic Marker by Global Gene Expression Meta-analysis
Cancer Res., December 15, 2005; 65(24): 11259 - 11264.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
M. Reedijk, S. Odorcic, L. Chang, H. Zhang, N. Miller, D. R. McCready, G. Lockwood, and S. E. Egan
High-level Coexpression of JAG1 and NOTCH1 Is Observed in Human Breast Cancer and Is Associated with Poor Overall Survival
Cancer Res., September 15, 2005; 65(18): 8530 - 8537.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
O. Modlich, H.-B. Prisack, M. Munnes, W. Audretsch, and H. Bojar
Immediate Gene Expression Changes After the First Course of Neoadjuvant Chemotherapy in Patients with Primary Breast Cancer Disease
Clin. Cancer Res., October 1, 2004; 10(19): 6418 - 6431.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
B. Weigelt, A. M. Glas, L. F. A. Wessels, A. T. Witteveen, J. L. Peterse, and L. J. van't Veer
Gene expression profiles of primary breast tumors maintained in distant metastases
PNAS, December 23, 2003; 100(26): 15901 - 15905.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2001 by the Society for Endocrinology.